RxDoctor Payments Data

Sheri Weinstein, MD

Internal Medicine · Sarasota, FLNPI 1881686822

Payments from drug & device makers

$1,377in general payments, 2019–2025

Across 62 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$418
  • AbbVie$223
  • Eisai Inc.$164
  • Pfizer$76
  • Merz North America, Inc.$60
  • Novo Nordisk$60
  • plus $376 from 16 others

What the payments were for

  • Food & beverage$1,36899%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,377 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$298,960
Medicare patients
161
Services billed
9,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$108,349
OzempicSemaglutide34$47,462
JardianceEmpagliflozin37$31,301
MyrbetriqMirabegron18$19,859
XareltoRivaroxaban14$16,249
JanuviaSitagliptin Phosphate16$15,187
Repatha SureclickEvolocumab25$14,494
ProgesteroneProgesterone, Micronized253$10,717
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,876
BrilintaTicagrelor14$6,143
Estradiol (Twice Weekly)Estradiol43$4,546
DottiEstradiol27$2,866
Febuxostat32$2,211
Liothyronine Sodium55$2,189
Estradiol19$2,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$108,34994 claims
Novo NordiskOzempic$60$47,46234 claims
Boehringer IngelheimJardiance$45$31,30137 claims
Astellas Pharma US IncMyrbetriq$16$19,85918 claims
GSKTrelegy Ellipta$49$6,87611 claims
AbbVieSynthroid$223$2,01929 claims
Acella Pharmaceuticals, LLCNp Thyroid$12$1,00218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →